Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

android tablet pc

Home > Press > World Malaria Day Casts Spotlight on New Funding to Portland Firm for Treatment of Malaria

DesignMedix completes Series A Financing and Adds Grant Dollars

World Malaria Day Casts Spotlight on New Funding to Portland Firm for Treatment of Malaria

Portland, OR | Posted on April 25th, 2009

Saturday, April 25 is World Malaria Day, an occasion instituted by the World Health Assembly to raise awareness about the deadly, mosquito-borne disease. Among those who are working to combat malaria is DesignMedix Inc., an early stage drug developer.

The company recently announced new funding for novel drugs to attack the disease, which infects more than 500 million people per year and kills more than one million. The company's drugs in development are more than ten-times more active than most other drugs. This enables lower cost of production and reduced safety concerns. They also overcome drug resistance, which has become a major worldwide concern. The drugs are being developed in partnership with Dr. David Peyton's laboratory in the chemistry department at Portland State University (PSU).

DesignMedix has completed Series A financing, raising just over $1 million. The financing includes funding from the Oregon Angel Fund, Angel Oregon 2009 LLC, Women's Investment Network, and Northwest Technology Ventures, as well as several private investors.

DesignMedix completed its current financing round in part with a recent win at the Oregon Entrepreneurs Network 2009 Angel Oregon Competition. The company was selected from a group of 50 entrepreneurial teams for the top investment prize of $150,000. DesignMedix was honored for the strength of its management team and its innovative technology for overcoming drug resistance.

"The company has a compelling and unique technology that could solve a major health problem," said Drew Smith, chairman of the judging panel.

In addition to the equity funding, DesignMedix's product development plans received additional support with the award of two major R&D grants. The Oregon Nanoscience and Microtechnologies Institute (ONAMI) awarded $246,000 for a joint project with Portland State University to develop nanotech formulations of the company's antimalarial drugs for prevention of malaria in travelers. The National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), provided a grant totaling over $1.3 million for drug development and preclinical studies. An additional grant from the government's stimulus funding to NIH is under review.

"The investment and awards reflect the fact the products DesignMedix is developing are important globally, and have the potential to save many lives," said Lynnor Stevenson, Ph.D., CEO of DesignMedix. "We are pleased to complete the funding in a difficult economic climate. The angel and investment community in Oregon has been very supportive of DesignMedix, and of our mission."

DesignMedix will use the funds to expand its product discovery efforts and take malaria drug candidate compounds forward into preclinical studies. In collaboration with PSU, OTRADI (Oregon Translational Research and Drug Development Institute) and the NIH, DesignMedix will investigate the application of the technology to other diseases.


About DesignMedix
DesignMedix was founded in 2006 to develop drugs to overcome drug resistance with an initial focus on curing malaria. The original technology, developed by Professor David Peyton, Ph.D., and licensed from Portland State University, has been further developed by the company to address malaria prevention and to treat other diseases that exhibit resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over a million people per year and affects up to 500 million people. The company has developed a series of novel drugs that have demonstrated efficacy and have the potential for low-cost production.

About Malaria and World Malaria Day

According to UNICEF, a child dies of malaria every 30 seconds in Africa.

Nearly one million children under five years old in sub-Saharan Africa die each year from the mosquito-borne disease. Approximately half of the world's population is at risk of malaria, particularly those living in lower-income countries. It infects more than 500 million people per year and kills more than 1 million. The burden of malaria is heaviest in sub-Saharan Africa but the disease also afflicts Asia, Latin America, the Middle East and even parts of Europe. World Malaria Day was instituted by the World Health Assembly at its 60th session in May, 2007, as a day for recognizing the global effort to provide effective control of malaria.

For more information, please click here

Lynnor Stevenson, Ph.D.
(503) 228-0451

Copyright © DesignMedix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

From Narrow to Broad July 30th, 2014

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

Harris & Harris Group Invests in UberSeq, Inc. July 16th, 2014

Harris & Harris Group Portfolio Company D-Wave Systems Closes a $28.4 Million Financing July 14th, 2014


New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014


University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014


New imaging agent provides better picture of the gut July 25th, 2014

Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

EPFL Research on the use of AFM based nanoscale IR spectroscopy for the study of single amyloid molecules wins poster competition at Swiss Physics Society meeting July 22nd, 2014

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE